Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:
Arrowhead Pharmaceuticals and partner Takeda Pharmaceuticals are nearing the completion of a mid-stage, placebo-controlled clinical trial of an RNA-based drug called fazirsiran in patients with alpha-1 antitrypsin deficiency, or AATD, an inherited disease that causes severe liver and lung damage. Participants in the study have undergone liver biopsies at baseline and one year to determine if fazirsiran improves disease symptoms, including liver fibrosis.
The Alzheimer’s disease treatment lecanemab slowed the rate of cognitive and functional decline compared to a placebo in a study enrolling roughly 1,800 patients with early-stage Alzheimer’s, its makers Eisai and Biogen announced earlier this week. Detailed data from the study are being presented at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting, starting on Nov. 29.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect